ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

The Future of Immune Checkpoint Inhibition in Gastric and Esophageal Cancers

Geoffrey Y. Ku, MD
Published Online:10:19 AM, Thu February 2, 2017

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of immune checkpoint inhibition in gastric and esophageal cancers.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.